The potential of BOT/BAL for patients who previously had limited treatment options – Agenus
Agenus shared a post on LinkedIn:
“Breaking News: Today, we announced the publication of new data in the Journal of Clinical Oncology. These findings highlight the potential of botensilimab and balstilimab for patients who previously had limited treatment options.
Learn more here.”
About Agenus
Agenus Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus has built a diverse pipeline of immune-modulating antibodies, cancer vaccines, and adoptive cell therapies.
The company’s approach to cancer immunotherapy is multifaceted, encompassing checkpoint inhibitors, bispecific antibodies, cell therapies, cancer vaccines, and adjuvants. Botensilimab, the company’s lead candidate, exemplifies its commitment to developing innovative immunotherapies to address unmet medical needs in oncology.
Read the post “Three decades of pioneering in Immune Oncology – Agenus” on oncodaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023